BUSULFEX Side Effects

6740646-9 | Acute Graft Versus Host Disease In Liver, Autoimmune Hepatitis
on May 12, 2010 Male patient from SPAIN , 33 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in liver, autoimmune hepatitis. Busulfex dosage: 16 Mg/kg. During the same period patient was treated with CYCLOPHOSPHAMIDE W VINCRISTINE PREDNISONE (CYCLOPHOSPHAMIDE, PREDNISON (View Cyclophosphamide W Vincristine Prednisone (cyclophosphamide, Prednison Review and Cyclophosphamide W Vincristine Prednisone (cyclophosphamide, Prednison Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6737778-8 | Bone Marrow Failure, Chimerism, Transplant Failure
Patient was taking Busulfex (View Usage). Patient had the following side effects: bone marrow failure, chimerism, transplant failure on May 21, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 229.7 lb, was diagnosed with acute myeloid leukaemia and. Busulfex dosage: 56mg 4x A Day Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (4200mg Once A Day Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ).

6732650-1 | Candidiasis, Granulocytopenia, Pancytopenia
Adverse event was reported on Apr 13, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 8 Mg/kg, Intraveous) was diagnosed with stem cell transplant and. Location: ISRAEL , child 3 years of age, After Busulfex was administered, patient had the following side effects: candidiasis, granulocytopenia, pancytopenia. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ENDOXAN NET (CYCLOPHOSPHAMIDE) (View Endoxan Net (cyclophosphamide) Review and Endoxan Net (cyclophosphamide) Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ), ATG (ANTI LYMPHOCYTE GLOBULIN) (View Atg (anti Lymphocyte Globulin) Review and Atg (anti Lymphocyte Globulin) Label ).

6730820-X | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Chronic Graft Versus Host Disease, Pancreatic Atrophy, Sicca Syndrome, Steatorrhoea, Weight Decreased
on May 07, 2010 Female patient from JAPAN , 41 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, chronic graft versus host disease, pancreatic atrophy, sicca syndrome, steatorrhoea, weight decreased. Busulfex dosage: Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).


6730166-X | Mucosal Inflammation, Neutropenia, Pneumonia Fungal, Thrombocytopenia
on Apr 30, 2010 Male patient from UNITED STATES , 28 years of age, was treated with Busulfex (View Usage). Patient had the following side effects: mucosal inflammation, neutropenia, pneumonia fungal, thrombocytopenia. Busulfex dosage: 5 Mg/kg, Intravenous. During the same period patient was treated with AMBISOME (View Ambisome Review and Ambisome Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), POSACONAZOLE (View Posaconazole Review and Posaconazole Label ), 5 FLUOROCYTOSINE (5 FLUOROCYSTOSINE) (View 5 Fluorocytosine (5 Fluorocystosine) Review and 5 Fluorocytosine (5 Fluorocystosine) Label ), CASPOFUNGIN (CASPOFUNGIN) (View Caspofungin (caspofungin) Review and Caspofungin (caspofungin) Label ), PALIFERMIN (PALIFERMIN) (View Palifermin (palifermin) Review and Palifermin (palifermin) Label ).

6722160-X | Gastrointestinal Toxicity, Hepatotoxicity, Mucosal Inflammation
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: gastrointestinal toxicity, hepatotoxicity, mucosal inflammation on May 03, 2010 from KOREA, REPUBLIC OF Additional patient health information: Female patient , 43 years of age, . Busulfex dosage: 130 Mg/m2, Unk, Intravenous. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ).

6722158-1 | Gastrointestinal Toxicity, Hepatotoxicity, Mucosal Inflammation, Venoocclusive Disease
Adverse event was reported on May 03, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: 130 Mg/m2, Unk, Intravenous) . Location: KOREA, REPUBLIC OF , 52 years of age, Patient experienced the following unwanted or unexpected effects: gastrointestinal toxicity, hepatotoxicity, mucosal inflammation, venoocclusive disease. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ).

6722156-8 | Abdominal Discomfort, Blood Bilirubin Increased, Hepatotoxicity, Liver Disorder, Mucosal Inflammation, Venoocclusive Disease
on May 03, 2010 Female patient from KOREA, REPUBLIC OF , 36 years of age, was treated with Busulfex (View Usage). Patient had the following side effects: abdominal discomfort, blood bilirubin increased, hepatotoxicity, liver disorder, mucosal inflammation, venoocclusive disease. Busulfex dosage: 130 Mg/m2, Unk, Intravenous. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ).

6722149-0 | Gastrointestinal Toxicity, Hepatotoxicity, Mucosal Inflammation
on May 03, 2010 Male patient from KOREA, REPUBLIC OF , 57 years of age, was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: gastrointestinal toxicity, hepatotoxicity, mucosal inflammation. Busulfex dosage: 130 Mg/m2, Unk, Intravenous. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ).

6720710-0 | Blood Bilirubin Increased, Gastrointestinal Toxicity, Mucosal Inflammation, Venoocclusive Disease
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, gastrointestinal toxicity, mucosal inflammation, venoocclusive disease on May 03, 2010 from KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF Additional patient health information: Female patient , 39 years of age, . Busulfex dosage: 130 Mg/m2 Intravenous. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ).

6713506-7 | Acute Graft Versus Host Disease In Liver, Fluid Retention
Adverse event was reported on Apr 30, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 0.8mg/kg, Q8hr, Intravenous) was diagnosed with stem cell transplant and. Location: JAPAN , 64 years of age, Patient had the following side effects: acute graft versus host disease in liver, fluid retention. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6713503-1 | Haematotoxicity, Neutropenia, Pleural Effusion
on Apr 30, 2010 Male patient from JAPAN , 64 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: haematotoxicity, neutropenia, pleural effusion. Busulfex dosage: 0.8mg/kg Q6hr, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), DASATINIB (View Dasatinib Review and Dasatinib Label ).

6710589-5 | Acute Graft Versus Host Disease In Liver, Acute Graft Versus Host Disease In Skin, Diarrhoea, Nausea, Neoplasm Progression
on Apr 23, 2010 Female patient from JAPAN , 56 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in liver, acute graft versus host disease in skin, diarrhoea, nausea (What is nausea?), neoplasm progression. Busulfex dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6710583-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Gamma-glutamyltransferase Increased, Liver Disorder
Patient was taking Busulfex (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, liver disorder on Apr 19, 2010 from JAPAN Additional patient health information: Male patient , 40 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 40 Mg, Qid, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6710404-X | Chronic Graft Versus Host Disease, Pancreatic Atrophy, Sicca Syndrome
Adverse event was reported on Apr 28, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: Oral) was diagnosed with stem cell transplant and. Location: JAPAN , 60 years of age, After Busulfex was administered, patient had the following side effects: chronic graft versus host disease, pancreatic atrophy, sicca syndrome. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6710385-9 | Cardiac Failure, Sepsis
on Apr 23, 2010 Male patient from NORWAY , 52 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure, sepsis (What is sepsis?). Busulfex dosage: 0.8 Mg/kg, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6710384-7 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Liver, Acute Graft Versus Host Disease In Skin, Sepsis
on Apr 23, 2010 Male patient from NORWAY , 56 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in liver, acute graft versus host disease in skin, sepsis (What is sepsis?). Busulfex dosage: 0.8 Mg/kg, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6710369-0 | Sepsis
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: sepsis (What is sepsis?) on Apr 23, 2010 from NORWAY Additional patient health information: Male patient , 61 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 0.8 Mg/kg, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6710367-7 | Leukaemia Recurrent
Adverse event was reported on Apr 23, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 0.8 Mg/kg, Intravenous) was diagnosed with stem cell transplant and. Location: NORWAY , 57 years of age, Patient experienced the following unwanted or unexpected effects: leukaemia recurrent. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE 9METHOTREXATE) (View Methotrexate 9methotrexate) Review and Methotrexate 9methotrexate) Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6710090-9 | Acute Graft Versus Host Disease In Skin, Anaemia, Clostridial Infection, Failure To Thrive, Hepatosplenomegaly, Hypogammaglobulinaemia, Hypophagia, Interstitial Lung Disease, Mycobacterium Chelonei Infection
on Apr 28, 2010 Female patient from UNITED STATES , weighting 12.79 lb, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in skin, anaemia, clostridial infection, failure to thrive, hepatosplenomegaly, hypogammaglobulinaemia, hypophagia, interstitial lung disease, mycobacterium chelonei infection. Busulfex dosage: 37.5 Mg/m2, Q6hr, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), THYMOGLOBULIN (View Thymoglobulin Review and Thymoglobulin Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6710074-0 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Chronic Graft Versus Host Disease, Pancreatic Atrophy, Sicca Syndrome, Steatorrhoea
on Apr 28, 2010 Female patient from JAPAN , 41 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, chronic graft versus host disease, pancreatic atrophy, sicca syndrome, steatorrhoea. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6701821-2 | Acute Graft Versus Host Disease In Skin, Anaemia, Clostridial Infection, Gene Mutation, Hepatosplenomegaly, Hypogammaglobulinaemia, Hypophagia, Lymphadenopathy, Malnutrition
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, anaemia, clostridial infection, gene mutation, hepatosplenomegaly, hypogammaglobulinaemia, hypophagia, lymphadenopathy, malnutrition on Apr 13, 2010 from UNITED STATES Additional patient health information: Female patient , child 8 years of age, weighting 12.79 lb, was diagnosed with stem cell transplant and. Busulfex dosage: 37.5 Mg/m2, Q6hr.. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), THYMOGLOBULIN (View Thymoglobulin Review and Thymoglobulin Label ), METHYLPERDNISOLONE (METHYLPREDNISOLONE) (View Methylperdnisolone (methylprednisolone) Review and Methylperdnisolone (methylprednisolone) Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6701481-0 | Acute Graft Versus Host Disease In Skin, Blood Count Abnormal, Diarrhoea, Rash Erythematous
Adverse event was reported on Apr 13, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: ) was diagnosed with stem cell transplant and. Location: UNITED STATES , 65 years of age, Patient had the following side effects: acute graft versus host disease in skin, blood count abnormal, diarrhoea, rash erythematous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6701263-X | Acute Graft Versus Host Disease In Liver, Fluid Retention
on Apr 13, 2010 Male patient from JAPAN , 64 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: acute graft versus host disease in liver, fluid retention. Busulfex dosage: 0.8 Mg/kg, Q6hr, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6701262-8 | Haematotoxicity, Pleural Effusion
on Apr 13, 2010 Male patient from JAPAN , 64 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: haematotoxicity, pleural effusion. Busulfex dosage: 0.8 Mg/kg, Q6hr, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), DASATINIB (View Dasatinib Review and Dasatinib Label ).

6701260-4 | Acute Respiratory Failure, Confusional State, Cytomegalovirus Infection, Interstitial Lung Disease, Pyrexia, Toxoplasmosis
Patient was taking Busulfex (View Usage). Patient had the following side effects: acute respiratory failure, confusional state, cytomegalovirus infection (What is cytomegalovirus infection?), interstitial lung disease, pyrexia, toxoplasmosis on Apr 13, 2010 from FRANCE Additional patient health information: Female patient , 15 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)) (View Atg (antilymphocyte Immunoglobulin (horse)) Review and Atg (antilymphocyte Immunoglobulin (horse)) Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CORTICOSTEROIDS FOR SYSTEMIC USE (View Corticosteroids For Systemic Use Review and Corticosteroids For Systemic Use Label ), CEFTAZIDIME (View Ceftazidime Review and Ceftazidime Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), METRONIDAZOLE (View Metronidazole Review and Metronidazole Label ).

6701259-8 | Candidiasis, Chimerism, Granulocytopenia, Pancytopenia
Adverse event was reported on Apr 13, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: 8 Mg/kg) was diagnosed with stem cell transplant and. Location: ISRAEL , child 3 years of age, After Busulfex was administered, patient had the following side effects: candidiasis, chimerism, granulocytopenia, pancytopenia. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ENDOXAN NET (CYCLOPHOSPHAMIDE) (View Endoxan Net (cyclophosphamide) Review and Endoxan Net (cyclophosphamide) Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) (View Atg (antilymphocyte Immunoglobulin (horse) Review and Atg (antilymphocyte Immunoglobulin (horse) Label ).

6701258-6 | Cardiotoxicity, Complications Of Bone Marrow Transplant, Diarrhoea, Graft Versus Host Disease, Infection, Leukopenia, Mucosal Inflammation, Myelodysplastic Syndrome, Skin Toxicity
on Apr 13, 2010 Female patient from GERMANY , 16 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: cardiotoxicity, complications of bone marrow transplant, diarrhoea, graft versus host disease, infection (What is infection?), leukopenia, mucosal inflammation, myelodysplastic syndrome, skin toxicity. Busulfex dosage: 1 Mg/kg. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

6701257-4 | Cardiotoxicity, Diarrhoea, Ewing's Sarcoma, Graft Versus Host Disease, Infection, Leukopenia, Mucosal Inflammation, Skin Toxicity, Thrombocytopenia
on Apr 13, 2010 Female patient from GERMANY , 22 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: cardiotoxicity, diarrhoea, ewing's sarcoma, graft versus host disease, infection (What is infection?), leukopenia, mucosal inflammation, skin toxicity, thrombocytopenia. Busulfex dosage: 1 Mg/kg, Qid. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).

6701256-2 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Liver, Acute Graft Versus Host Disease In Skin, Chronic Graft Versus Host Disease, Pancreatic Atrophy, Sicca Syndrome
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in liver, acute graft versus host disease in skin, chronic graft versus host disease, pancreatic atrophy, sicca syndrome on Apr 13, 2010 from JAPAN Additional patient health information: Male patient , 60 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6701249-5 | Blood Bilirubin Increased, Confusional State, Convulsion, Headache, Hepatic Enzyme Increased, Hepatotoxicity, Intracranial Pressure Increased, Vision Blurred, Vomiting
Adverse event was reported on Apr 13, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: Intravenous) was diagnosed with stem cell transplant and. Location: ITALY , 17 years of age, Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, confusional state, convulsion, headache (What is headache?), hepatic enzyme increased, hepatotoxicity, intracranial pressure increased, vision blurred, vomiting. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6701248-3 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Chronic Graft Versus Host Disease, Pancreatic Atrophy, Sicca Syndrome, Steatorrhoea
on Apr 13, 2010 Female patient from JAPAN , 41 years of age, was diagnosed with transplant and was treated with Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, chronic graft versus host disease, pancreatic atrophy, sicca syndrome, steatorrhoea. Busulfex dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6701239-2 | Convulsion, Neurotoxicity
on Apr 13, 2010 Female patient from ITALY , child 8 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: convulsion, neurotoxicity. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)) (View Atg (antilymphocyte Immunoglobulin (horse)) Review and Atg (antilymphocyte Immunoglobulin (horse)) Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6701238-0 | Convulsion, Graft Versus Host Disease, Neurotoxicity
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, graft versus host disease, neurotoxicity on Apr 13, 2010 from ITALY Additional patient health information: Female patient , child 11 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6701237-9 | Convulsion, Intracranial Pressure Increased, Neurotoxicity
Adverse event was reported on Apr 13, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: Intravenous) was diagnosed with stem cell transplant and. Location: ITALY , child 9 years of age, Patient had the following side effects: convulsion, intracranial pressure increased, neurotoxicity. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ).

6701236-7 | Convulsion, Neurotoxicity
on Apr 13, 2010 Male patient from ITALY , child 12 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: convulsion, neurotoxicity. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)) (View Atg (antilymphocyte Immunoglobulin (horse)) Review and Atg (antilymphocyte Immunoglobulin (horse)) Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ).

6701235-5 | Cough, Influenza, Rhinitis
on Apr 13, 2010 Male patient from TUNISIA , weighting 11.02 lb, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: cough, influenza, rhinitis. Busulfex dosage: 16 Mg/kg, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6701234-3 | Convulsion, Neurotoxicity
Patient was taking Busulfex (View Usage). Patient had the following side effects: convulsion, neurotoxicity on Apr 13, 2010 from ITALY Additional patient health information: Male patient , 14 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ATG (ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)) (View Atg (antilymphocyte Immunoglobulin (horse)) Review and Atg (antilymphocyte Immunoglobulin (horse)) Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CLONAZEPAM (CLONAZEPAM0 (View Clonazepam (clonazepam0 Review and Clonazepam (clonazepam0 Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6701233-1 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Influenza
Adverse event was reported on Apr 13, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: 16 Mg/kg, Intravenous) was diagnosed with stem cell transplant and. Location: TUNISIA , child 5 years of age, weighting 28.66 lb, After Busulfex was administered, patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, influenza. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6701232-X | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Dyspnoea, Herpes Zoster, Kaposi's Sarcoma, Pulmonary Fibrosis, Venoocclusive Liver Disease, Weight Decreased
on Apr 13, 2010 Male patient from ITALY , 57 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, chronic graft versus host disease, dyspnoea, herpes zoster, kaposi's sarcoma (What is kaposi's sarcoma?), pulmonary fibrosis (What is pulmonary fibrosis?), venoocclusive liver disease, weight decreased. Busulfex dosage: . During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6694968-0 | Fatigue, Intravascular Haemolysis, Multi-organ Failure, Pyrexia, Renal Failure Acute, Transplant Rejection, Vertigo, Vomiting
on Mar 29, 2010 Male patient from JAPAN , 60 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: fatigue, intravascular haemolysis, multi-organ failure, pyrexia, renal failure acute, transplant rejection, vertigo, vomiting. Busulfex dosage: Intravenous. During the same period patient was treated with MICAFUNGIN (MICAFUNGIN) (View Micafungin (micafungin) Review and Micafungin (micafungin) Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CEFEPIME (View Cefepime Review and Cefepime Label ).

6692958-5 | Chronic Graft Versus Host Disease, Chronic Myeloid Leukaemia, Disease Progression, Pyrexia
Patient was taking Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: chronic graft versus host disease, chronic myeloid leukaemia, disease progression, pyrexia on Apr 05, 2010 from ITALY Additional patient health information: Female patient , 50 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), NILOTINIB (NILOTINIB) (View Nilotinib (nilotinib) Review and Nilotinib (nilotinib) Label ).

6692777-X | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Condition Aggravated, Myelodysplastic Syndrome
Adverse event was reported on Apr 05, 2010 by a Female patient taking Busulfex (View Usage) (Dosage: ) was diagnosed with stem cell transplant and. Location: UNITED STATES , 60 years of age, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, chronic graft versus host disease, condition aggravated, myelodysplastic syndrome. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), DECITABINE (DECITABINE) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ).

6692767-7 | Acute Graft Versus Host Disease, Condition Aggravated, Myelodysplastic Syndrome
on Apr 05, 2010 Male patient from UNITED STATES , 66 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient had the following side effects: acute graft versus host disease, condition aggravated, myelodysplastic syndrome. Busulfex dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), AZACITIDINE (AZACITIDINE) (View Azacitidine (azacitidine) Review and Azacitidine (azacitidine) Label ).

6692545-9 | Cystitis Haemorrhagic, Hypertension, Multiple Myeloma, Myeloma Recurrence, Rash, Renal Failure Acute
on Apr 12, 2010 Male patient from UNITED STATES , 52 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: cystitis haemorrhagic, hypertension, multiple myeloma (What is multiple myeloma?), myeloma recurrence, rash (What is rash?), renal failure acute. Busulfex dosage: Intravenous. During the same period patient was treated with ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6692435-1 | Disease Recurrence, Myelodysplastic Syndrome
Patient was taking Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: disease recurrence, myelodysplastic syndrome on Apr 05, 2010 from UNITED STATES Additional patient health information: Female patient , 62 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), AZACITIDINE (AZACITIDINE) (View Azacitidine (azacitidine) Review and Azacitidine (azacitidine) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ).

6692345-X | Brain Stem Haemorrhage, Encephalitis Viral, Muscle Spasms, Rash, Thrombotic Microangiopathy
Adverse event was reported on Feb 25, 2010 by a Male patient taking Busulfex (View Usage) (Dosage: ) . Location: JAPAN , child 12 years of age, Patient had the following side effects: brain stem haemorrhage, encephalitis viral, muscle spasms, rash (What is rash?), thrombotic microangiopathy. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

6691558-0 | Blast Cell Crisis, Chronic Myeloid Leukaemia, Leukaemia Recurrent, Stenotrophomonas Infection, Streptococcal Infection
on Apr 05, 2010 Female patient from ITALY , 57 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). After Busulfex was administered, patient had the following side effects: blast cell crisis, chronic myeloid leukaemia, leukaemia recurrent, stenotrophomonas infection, streptococcal infection (What is streptococcal infection?). Busulfex dosage: Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTITHYMOCYTE IMMUNOGLOBULIN (View Antithymocyte Immunoglobulin Review and Antithymocyte Immunoglobulin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), NILOTINIB (View Nilotinib Review and Nilotinib Label ), DASATINIB (View Dasatinib Review and Dasatinib Label ), IMATINIB MESYLATE (View Imatinib Mesylate Review and Imatinib Mesylate Label ).

6686069-2 | Acute Graft Versus Host Disease In Liver, Adenocarcinoma, Hypercalcaemia, Lung Infection, Lung Neoplasm Malignant, Pleural Effusion
on Apr 07, 2010 Male patient from FRANCE , 40 years of age, was diagnosed with stem cell transplant and was treated with Busulfex (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in liver, adenocarcinoma, hypercalcaemia, lung infection, lung neoplasm malignant, pleural effusion. Busulfex dosage: 16 Mg/kg Oral. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6686064-3 | Organising Pneumonia, Pneumocystis Jiroveci Pneumonia, Respiratory Failure
Patient was taking Busulfex (View Usage). Patient had the following side effects: organising pneumonia, pneumocystis jiroveci pneumonia, respiratory failure on Apr 05, 2010 from JAPAN Additional patient health information: Male patient , child 6 years of age, was diagnosed with stem cell transplant and. Busulfex dosage: 1.1 Mg/kg Intravenous. During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ).